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study question: Do injectable and oral contraceptives increase the risk of human immunodeﬁciency virus (HIV) acquisition in women?
summaryanswer: After adjusting for confounders, evidence of a signiﬁcantly increased risk of HIV remained for women using injectable
depo-medroxyprogesterone (DMPA) (hazard ratio ¼ 1.49, 95% conﬁdence interval (1.06–2.08)) but not for injectable norethisterone-
enanthate (Net-En) or oral contraceptive pills (OC).
what is known already: An association between the use of some types of hormonal contraception (HC)methods and an increased
risk of HIV, possibly through changes in the genital tract environment and alterations in the immune response, has been previously observed, al-
though not consistently. A recent systematic review of these studies has highlighted the need for more deﬁnitive evidence.
study design, size, duration: A secondary data analysis of the MDP301 phase 3 microbicide trial was conducted to estimate the
effects of use of differentmethods of HCon the risk of HIV acquisition in women. HIV-negativewomen (n ¼ 8663)with amedian age of 28 years
were included in the analysis; 382 HIV seroconverted by 52 weeks follow-up; 10% of women-years were lost to follow-up before 52 weeks.
participants/materials, setting, methods: Contraceptive use was reported at each 4-weekly visit. Cox proportional
hazards (PH) models were used to estimate the effects of baseline and current use of injectable DMPA, injectable Net-En and OC compared
with no HC, on the risk of HIV, adjusting for baseline and time-updated covariates. Causal effects for 52 weeks of HC use compared with no
HC were estimated in a weighted Cox model, censoring women at deviation from baseline HC use (or non-use) or pregnancy.
main results and the role of chance: At baseline, 2499 (29%) women were on DMPA, 1180 (14%) on Net-En, and 1410
(16%) on OC; 3574 (40%) not on HC, started HC in follow-up. Adjusted hazard ratios (HR) for baseline HC use, compared with no HC,
were 1.38 (95% conﬁdence interval (CI) 1.07–1.78) for DMPA; 1.18 (0.86–1.62) for Net-En and 0.97 (0.68–1.38) for OC. The estimated
causal effects of DMPA and Net-En over 52 weeks were: HR ¼ 1.49 (95% CI 1.06–2.08) and HR ¼ 1.31 (95% CI 0.62–1.61), respectively.
limitations, reasons forcaution: Amain limitationof the studywas that itwas a secondaryanalysisof data froma study thatwas
not designed to investigate this question. Despite our best efforts, we cannot exclude residual confounding to explain the effect of DMPA.
wider implications of the findings: The results of this study should be reviewed by theWorld Health Organization to deter-
mine whether current recommendations on the use of DMPA in settings with high HIV prevalence require modiﬁcation.
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commercial organizations,which is fundedby theUKGovernment (DFID andMRC),with support from IPMandEDCTP.The funders had no role
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Introduction
A number of epidemiological studies have investigated the relationship
between the use of different oral and injectable hormonal contraception
(HC) andpossible increased riskof human immunodeﬁciency virus (HIV)
infection.A recent systematic reviewof thesehashighlighted theneed for
moredeﬁnitive evidence (Polis andCurtis, 2013). Therearepossible bio-
logical mechanisms which might explain a potential elevated risk, includ-
ing changes in the genital tract environment and alteration of immune
response (Marx et al., 1996; Trunova et al., 2006; Hel et al., 2010). In
early 2012, the World Health Organization (WHO) issued a technical
statement following a review of the available evidence. While they did
not propose any restrictions on the use of hormonal contraception
(HC), for women at high risk of HIV they added a clariﬁcation to their
guidance stating: ‘because of the inconclusive nature of the body of evi-
dence on possible increased risk of HIV acquisition, women using
progestogen-only injectable contraception should be strongly advised
to also always use condoms, male or female, and other HIV preventive
measures.’ (WHO, 2012).
In the absence of any RCT of HC methods and HIV acquisition in
women,observational data fromHIVprevention trials provide anoppor-
tunity to investigate this question.Weaimed to estimate the effect ofHC
use on the risk of HIV acquisition using a large dataset drawn from the
MDP301 phase 3 microbicide trial. Data came from six African sites
with high HIV incidence and included 4-weekly collection of data on
contraception to 52 weeks follow-up after enrolment.
Note that we use the term ‘hormonal contraception’ to mean inject-
able and oral contraceptives.
Methods
Data
The trial design, methods and results have been described elsewhere (Nunn
et al., 2009; McCormack et al., 2010; Pool et al., 2010a,b). Brieﬂy, MDP301
was a phase 3 double blind randomized placebo-controlled trial investigating
the safety and efﬁcacyof the candidatemicrobicide PRO2000, formulated in a
gel and inserted prior to sex via a vaginal applicator. Trial registration:
ISRCTN64716212. A total of 9385 women were enrolled from six centres
from four sub-Saharan African countries: three centres in South Africa and
one each in Uganda, Tanzania and Zambia. HIV-negative women aged 16
or older (age 18 years or older in South Africa and Zambia) were recruited
in a range of settings and in Uganda were recruited as sero-discordant
coupleswith theirHIV-positive partner. The primary end-pointwas incidence
of HIV infection over 52 weeks of follow-up and the study concluded that
there was no evidence that PRO2000 gel protected women from HIV infec-
tion. A total of 8663 HIV-negative women were included in the present ana-
lysis. Those excluded were: 69 participants found to be HIV positive at
enrolment, 458who had no follow-up data onHIV and a further 18 using hor-
monal implants who were considered too few to form a separate group for
analysis. In addition 177 participants aged 51 years or above were also
excluded as being beyond reproductive age. Participants reported contracep-
tion at baseline and then at each 4-weekly visit through toWeek 52.
Outcome
During the 52 weeks follow-up, the 8663 study participants contributed a
total of 8122 person-years (py) for analysis. HIV testing occurred at
Weeks 12, 24, 40 and 52 and results were conﬁrmed in a central laboratory
(Jentsch et al., 2012). Follow-up time was measured from enrolment to the
date of the earliest positive HIV test, last follow-up visit or Week 52. A
total of 382 incident HIV infections were included in the analysis.
Exposure
Data on contraception were collected every 4 weeks from enrolment from
the following question in the sexual behavioural case record form: ‘Are you
currently using any form of family planning?’ Where available, these data
were cross-checked with the contraception dispensing data. Responses for
type of HC were categorized for analysis as: (i) injectable depo-
medroxyprogesterone (DMPA) (ii) injectable norethisterone enanthate
(Net-En); (iii) oral contraceptive pills (OC) and (iv) not using HC (the refer-
ence category). This reference category was chosen to aid comparison with
previous studies and included the following types of contraception: no
contraception (44% at baseline); condoms for family planning (male or
female) (50% at baseline); natural or traditional methods (e.g. wooden
band or local herbs) (4% at baseline); sterilization (1% at baseline); intrauter-
ine contraceptive device (1% at baseline).
Note thatdatacollectedonOCdidnotdistinguishbetweendifferent types
of pill. In the setting of this study however it was likely that the combinedOC
would have been used.
Covariates
Baseline variables consideredwere: socio-demographic (age, centre, educa-
tion, employment status, randomized gel group); sexual behaviour (age of
ﬁrst sexual intercourse, sexual frequency during the last 7 days, condom
use at last sex act, anal sex in last 4 weeks, sex during menses and number
of sexual partners (reported in the last 4 weeks)); reported genital history
(unusual discharge, itching, ulcers and ectopy); and laboratory ﬁndings
(describedbelow).Covariatesmeasured in follow-upwere: sexual frequency
during the last 7 days and condom use at last sex act (4-weekly); genital ﬁnd-
ings reported every 4 weeks; urine tests for pregnancy taken 4-weekly from
enrolment; herpes simplex virus (HSV)-2 serology (for those HSV-2 sero-
negative at enrolment) and conﬁrmed by the central laboratory at Weeks
0, 40 and52; presenceofNeisseria gonorrhoea (NG), orChlamydia trachomatis
determined from an endocervical swab taken atWeeks 0 and 24; Trichomo-
nas vaginalisdiagnosedusing the InPouchculturemethodalso atWeeks0and
24; syphilis determined serologically at Weeks 0, 40 and 52; bacterial vagin-
osis (Ison Hay) at Weeks 0, 12, 24, 40 and 52. Additional tests were per-
formed at unscheduled visits if indicated.
All covariates (including contraception)measured in follow-upwere taken
from the last reported visit. Formissed visits or at visits where tests were not
scheduled, we carried forward the value from the previous visit. A sensitivity
analysis was performed to assess the effect of missed visits.
Statistical methods
Coxproportional hazardsmodelswereused toestimate thehazard ratios for
HIV acquisition associated with DMPA, Net-En and OC compared with no
HC. The parameters of the Cox models were estimated by pooled logistic
regression models, modelling the change in baseline hazard since enrolment
using a restricted cubic spline with knots at the 10th, 50th and 90th percen-
tiles (Weeks 8, 28 and 48). Datawere organized into 4-weekly intervals, cor-
responding to the visit schedule. Time-dependent variables were the most
recent values up to the start of each interval. Separate models were ﬁtted
for the effect of baseline useof contraception and currentuseof contraception
on risk of HIV acquisition adjusting for baseline and time-updated covariates.
A limitation of the baselinemodel is that it does not account for starting, stop-
ping or changing type ofHCduring the study; a limitation of the currentmodel
is that it does not appropriately adjust for time-dependent confounders
which may be affected by past HC exposure (although marginal structural
models and Cox PH models have given similar results in previous studies
(Heffron et al., 2012; McCoy et al., 2013)). To attempt to estimate the
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causal hazard ratio of HC use on HIV risk over 52 weeks, compared with 52
weeks of no HC use in non-pregnant women we used a weighted Cox pro-
portional hazards model. Women were ‘artiﬁcially censored’ at their ﬁrst
change in baseline HC or non-use of HC (starting, stopping or switching
type) or ﬁrst positive pregnancy test. The association between baseline
HC andHIV diagnosis was estimated using inverse-probability-of-censoring-
weights to account for artiﬁcial censoring, and direct adjustment for baseline
covariates to adjust for predictors of baseline HC group (Robins et al., 2000;
Hernan et al., 2006; Cole andHernan, 2008).While some information is lost
(artiﬁcial censoring, including censoring for pregnancy, resulted in 100 HIV
infections and 23% of person-years being excluded from the analysis), this
model corrects for starting, stopping, changing HC type during follow-up
and allows for measured time-dependent confounders appropriately. It
has the advantage over a standard MSM in that the type of contraception
used at the time of HIV infection (for included outcomes) is known, as
data are censored at ﬁrst change inHCandHIV infection is at the ﬁrst positive
HIV test. Full details on the casualmodel are given in the SupplementaryData.
The following sensitivity analyses were also performed and were
conducted on the ﬁnal adjusted baseline HC model and current HC model
on the full dataset. A previous study showed age and HSV-2 to be signiﬁcant
effect modiﬁers, with larger effects of HC found for women using HC
who were under 25 years or who were HSV-2 negative at enrolment
(Morrison et al., 2010) and another study also showed effect modiﬁcation
for age (Morrison et al., 2012). Therefore, age (,25 years versus ≥25
years), HSV-2 status at enrolment and centre (to test for consistency of
the results between the different trial populations) were investigated as
effect modiﬁers by tests for interaction. It should be noted that
other studies have failed to ﬁnd evidence of effect modiﬁcation (Heffron
et al., 2012; McCoy et al., 2013).
There is potential differential HIV risk behaviour within the no HC group,
with women using condoms for contraception likely to use condoms more
consistently (compared with those using other non-hormonal methods)
and hence to be at lower risk of HIV infection. We therefore conducted an
analysis separating out those in the no HC group who reported using
condoms as their main method of contraception, as a separate group.
Finally to exclude any possible effect of long-term cumulative exposure to
HC, we repeated the analysis restricted to thosewhowere not onHC at the
screening visit (which occurred up to 6 weeks before enrolment).
All analyses were performed in Stata (version 12.1). A value of P, 0.05
was considered signiﬁcant.
Results
Baseline use of HC
Baseline characteristics of study participants by use of HC at baseline are
shown in Table I: 2499 (29%) women were on DMPA, 1180 (14%) on
Net-En, 1410 (16%) on OC and 3574 (41%) on no HC at enrolment.
There were notable differences in HC use between centres, with inject-
ableHCusemore common in the SouthAfrican sites, and themajority of
Net-En users enrolled through Johannesburg. OCwasmore common in
Zambia.Youngerwomenweremore likely tobeprescribedHC,particu-
larly Net-En. Net-En users weremore likely to have had secondary edu-
cation and less likely to be employed.Net-En userswere alsomore likely
to report using a condomat the last sex act andhaving sexduringmenses.
NotablyOCuserswere less likely to reportusing acondomat the last sex
act at baseline.Women on noHCwere more likely to report not having
sex theweek prior to enrolment andweremore likely to report a history
of genital symptoms and to have positive laboratory ﬁndings for some
sexually transmitted infections.
Changing HC use in follow-up
Table II describes the changing use of HC during the study. Overall, 64%
remained on their baseline contraception in follow-up. Of the 3574
women who were on no HC at baseline, 2130 (60%) remained so in
follow-up, while 1444 (40%) started HC during follow-up (449 DMPA,
227 Net-En and 768 OC). Of the 5089 women who started on HC,
3407 (67%) remained on the same type of HC in follow-up.
HIV incidence by HC use at enrolment
Table III showsHIV incidence byHCat baseline. A total of 382HIV infec-
tions resulted in HIV incidence of 6.2 per 100 py for baseline DMPA
users; 6.3 per 100 py for Net-En users, 3.8 per 100 py for OC users
and 3.5 per 100 py for no HC users. Incidence was highest in Durban,
South Africa and lowest in Mwanza, Tanzania; it was highest in the
under 25 year age group and for those who tested positive for HSV2
at baseline. The proportion of women lost to follow-up (prior to HIV
seroconversion) was similar across baseline HC groups: 9, 10, 11 and
10% for DMPA, Net-En, OC and No HC, respectively.
Risk factors for HIV infection
The following baseline factors were found to be independently asso-
ciatedwithHIV risk: age, centre andHSV-2 result. Time-updated covari-
ates found to be independently associated with HIV were vaginal
discharge, chlamydia, bacterial vaginosis and HSV-2. Although not asso-
ciated with HIV, the randomized gel groupwas also included in the base-
line and time-updated covariate adjustedHIV outcomemodels. Neither
frequency of sex nor reported condom use was independently asso-
ciated with HIV outcomes in this dataset (neither at baseline nor follow-
up), but were included in the baseline and time-updated covariate
adjusted HIV outcome models.
Pregnancy in follow-up
In total 908 women became pregnant in follow-up: 122 (5%) among
those using DMPA at baseline; 58 (5%) for baseline Net-En users; 247
(18%) for baseline OC users and 481 (13%) for baseline no HC users.
Pregnancy was included in the time-updated covariate adjusted model,
although it was not found to be a signiﬁcant predictor of HIV risk:
HR ¼ 1.21 (95% CI 0.75–1.95).
Effect of HC on risk of HIV
Table IV(a) shows the effect ofHCon riskofHIVacquisition. The univari-
able unadjusted effects of baselineHC use, compared with no HC, were
HR ¼ 1.79 (95%CI 1.41–2.28) forDMPA, 1.80 (1.34–2.43) forNet-En
and 1.09 (0.78–1.52) for OC. After adjusting for baseline factors, the
effects for DMPA and Net-En reduced to 1.38 (1.07–1.78) and 1.18
(0.86–1.62), respectively, while the OC effect was similar to the un-
adjusted effect, 0.97 (0.68–1.38).
Results frommodelsmeasuring theeffectofcurrentHCusewerebroadly
similar to thebaselineHCeffects. Including time-updatedcovariates slightly
increased the effect for DMPA: HR ¼ 1.45 (95% CI 1.09–1.93) and
Net-En, HR ¼ 1.20 (95% CI 0.84–1.69). This model included sexual be-
havioural factors (sexual frequency and condom use) and pregnancy.
Table IV(b) shows the estimated hazard ratios where data were cen-
sored at the point of the ﬁrst change in HC (stopping, starting or switch-
ing) or pregnancy. Full details of the causal model are given in the
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Supplementary data. Results from ﬁtting the same univariable and base-
line adjusted models as were ﬁtted on the full dataset produced larger
effects in this reduced dataset. However after adjusting for the artiﬁcial
censoring and censoring for pregnancy (as well as natural censoring),
the weighted model gave similar results to the previous adjusted
models on the full dataset, with the DMPA effect remaining consistently
signiﬁcant and elevated in all models, causal HR ¼ 1.49 (95% CI 1.06–
2.08).
Interactions were tested on the baseline effect models on the full
dataset. None of the pre-speciﬁed interactions were signiﬁcant, with
.............................................................................................................................................................................................
Table I Baseline characteristics of women by hormonal contraception (HC) use at enrolment.
Characteristic Injectable DMPA
(n5 2499)
Injectable Net-En
(n5 1180)
OC (n5 1410) No HC (n5 3574) Total
N5 8663
P
Trial site
Durban, SA 972 (39) 297 (25) 195 (14) 853 (24) 2317 (27) ,0.001
Johannesburg, SA 417 (17) 731 (62) 317 (22) 895 (25) 2360 (27)
Africa Centre, SA 356 (14) 82 (7) 69 (5) 508 (14) 1016 (12)
Masaka, Uganda 277 (11) 0 (0) 55 (4) 454 (13) 786 (9)
Mwanza, Tanzania 238 (13) 0 (0) 186 (13) 511 (14) 1025 (12)
Mazabuka, Zambia 149 (6) 69 (6) 588 (42) 353 (10) 1159 (13)
Socio-demographic
Age (mean (SD)) 28.0 (7.4) 24.7 (6.0) 28.3 (7.2) 32.4 (9.4) 29.9 (9.5)
16–24 years 1022 (41) 718 (61) 533 (38) 990 (27) 3263 (37)
25–34 years 957 (38) 355 (30) 582 (41) 1044 (29) 2938 (34) ,0.001
35–44 years 465 (19) 101 (9) 267 (19) 1056 (30) 1889 (22)
45–50 years 55 (2) 6 (1) 28 (2) 484 (14) 573 (7)
Education
None/primary 1948 (78) 674 (57) 1116 (79) 2803 (78) 6541 (76) ,0.001
Secondary/tertiary 551 (22) 506 (43) 294 (21) 771 (22) 2122 (24)
Employed 621 (25) 151 (13) 334 (24) 972 (27) 2078 (24) ,0.001
Sexual behaviour
Age of ﬁrst sex
,14 years 177 (7) 38 (3) 119 (9) 260 (7) 594 (7) ,0.001
17–20 years 2010 (81) 1021 (87) 1067 (77) 2788 (78) 6886 (80)
.21 years 307 (12) 118 (10) 204 (15) 507 (14) 1136 (13)
Sexual frequencya (median (IQR)) 2 (1–3) 2 (1–4) 2 (1–4) 2 (1–3) 2 (1–3) ,0.001
No sex in last 7 days 454 (18) 158 (13) 193 (14) 822 (23) 1627 (19) ,0.001
Condom at last sex act 1404 (56) 795 (68) 549 (39) 2228 (62) 4976 (57) ,0.001
Anal sex 37 (1) 9 (1) 16 (1) 32 (1) 94 (1) 0.115
Sex during menses 70 (3) 87 (8) 73 (5) 126 (4) 356 (4) ,0.001
Genital ﬁndings
Discharge (history) 633 (25) 257 (22) 268 (19) 970 (27) 2128 (25) ,0.001
Itching (history) 608 (24) 159 (14) 309 (22) 992 (28) 2068 (24) ,0.001
Ulcers (history) 280 (11) 66 (5) 104 (7) 458 (13) 908 (10) ,0.001
Ectopy, ≥1% (exam) 436 (17) 206 (17) 218 (15) 421 (12) 1281 (15) ,0.001
Positive laboratory test ﬁndings
HSV-2 1614 (66) 567 (50) 855 (62) 2438 (70) 5474 (65) ,0.001
Chlamydia trachomatis 246 (10) 158 (14) 78 (6) 200 (6) 682 (8) ,0.001
Neisseria gonorrhoea 108 (4) 39 (3) 29 (2) 108 (3) 284 (3) 0.002
Syphilis 89 (4) 29 (2) 42 (3) 164 (5) 324 (4) 0.002
Trichomonas vaginalis 207 (8) 94 (8) 104 (7) 409 (12) 814 (9) ,0.001
Bacterial vaginosis 807 (32) 409 (35) 494 (35) 1420 (40) 3130 (36) ,0.001
Values are n (%) unless otherwise stated; P-values are from Chi-square tests or one-way analysis of variance as appropriate.
DMPA, depo-medroxyprogesterone; Net-En, norethisterone-enanthate; OC, oral contraceptive pill; IQR, inter-quartile range; HSV-2, herpes simplex virus.
aDuring last 7 days.
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the results consistent across age groups (P ¼ 0.71), HSV-2 status at en-
rolment (P ¼ 0.61) and centre (P ¼ 0.59).
Our ﬁndings were also robust to a number of sensitivity analyses.
Restricting the analyses to those who never missed more than two con-
secutive visits (79%) gave similar results to the full dataset. Similarly,
restricting to those who reported not using a condom at least twice in
follow-up (82%) also gave similar results. The HC effects also remained
unaffected by creating a separate category for those reporting using a
condom speciﬁcally for family planning purposes (from the no HC
group). There was no difference in the risk of HIV for those reporting
using a condom for family planning compared with the remainder of
the no HC group: HR ¼ 0.97 (95% CI 0.64–1.46) and effects for
DMPA,Net-en andOCwere similar to themain ﬁndings. Finally, restrict-
ing the analysis to thosewhowere not onHCat screening (up to 6weeks
prior to enrolment) also gave similar results (data not shown).
Discussion
We found amodest elevated risk (with a relativelywideCI) of HIV acqui-
sition forDMPAuse thatwewere not able to explain from themeasured
confounders in this dataset. Our effect estimate for Net-En suggests a
moderately increased risk of HIV but this was not statistically signiﬁcant.
Therewas no evidenceof an effect ofOCon risk. This is the largest single
study to date to report on this question and the results are similar (in
terms of magnitude of effect sizes) to those found in three recently
reported studies (Heffron et al., 2012; Morrison et al., 2012; McCoy
et al., 2013). Not all studies have found an association between use of in-
jectableHCand increased riskofHIV, and because previous studies have
useda rangeofmethods, sample sizes anddataof variablequality, as high-
lighted in a recent systematic review (Polis and Curtis, 2013), these
factors could in part explain the variable ﬁndings. As far as possible we
followed the recommended approaches to analyses for investigating
this question (Polis et al., 2013).
Two particular strengths of this dataset were 4-weekly reporting of
contraception and condom use and the ability to distinguish between
DMPA and Net-En. Recent research has suggested possible differential
biological pathways of different progestins used in contraception that
may have a role in increasing susceptibility to HIV acquisition (Tomasic-
chio et al., 2013). Although our results for Net-En were less consistent,
the effects were consistently signiﬁcant for DMPA.
The OC group is prone to miss-speciﬁcation as user-dependent
methods are commonly associated with lower adherence, backed up
in this dataset by the higher pregnancy rates observed in the OC group
comparedwith the other groups. Although some injectables were deliv-
ered in the study clinics, therewas still substantial reliance on self-report
from the participant and the timing of each injection could not be deter-
mined in this dataset. The sexual behavioural data, including condomuse,
are similarly prone tomisreporting. In this dataset, although condomuse
was not associated with a lower risk of HIV acquisition, it was associated
with lower risk of pregnancy (HR ¼ 0.73, 95% CI (0.63, 0.84) among
those not using injectables).While we acknowledge these limitations in-
herent in the dataset, we found our results to be robust to a number of
different sensitivity analyses including an analysiswhich excluded users of
condoms for family planning purposes fromthenoHCgroup. Important-
ly our ﬁndings were consistent across centres. A unique feature of the
dataset is that the Ugandan site enrolled sero-discordant couples
where women knew they were at risk of HIV infection, which may not
have been the case elsewhere. Similar to recent studies we found no evi-
dence of effect modiﬁcation for age or HSV2 status (Heffron et al., 2012;
McCoy et al., 2013).
A main limitation of the study was that it was a secondary analysis of
data from a study that was not designed to investigate this question.
The causal effect model aimed to emulate results that would be seen
in aRCT inwhich adherence to52weeksofHCusewasperfect.Weesti-
mated the effect of 52 weeks of HC use by type by artiﬁcially censoring
and weighting for ﬁrst change in baseline HC, assuming the adjustment
for baseline covariates appropriately allowed for differences in baseline
HC choice. By only including follow-up time on baseline HC and conser-
vatively using the date of ﬁrst positive HIV test as date of infection, we
avoided ambiguity regarding the type of HC use at infection. Our
hazard ratios can be interpreted as average effects over 52 weeks.
Despite our best efforts, we cannot exclude residual confounding to
explain the effect of DMPA, and a RCT of HC methods is currently
being planned to address this (Morrison and Nanda, 2012). However,
time-dependent confounding could still occur, with switching and preg-
nancy likely. Further, it is highly probable that there will be differential
condom use if theWHO recommendations are followed, and measuring
this, together with sexual behaviour, would rely on self-report. These
methodological concerns have raised questions regarding the value of
such a trial (Gollub and Stein, 2012; Morrison and Nanda, 2012; Ralph
et al., 2013, 2014; Cates, 2014), and the investigators acknowledge the
...................................................................................................................................................
.............................................................................................................................................................................................
Table II HC use at baseline and follow-up.
Contraception at enrolment
Injectable DMPA
(n5 2499)
Injectable Net-En
(n 5 1180)
Oral contraception
(n5 1410)
No hormonal
contraception (n 5 3574)
Contraception during follow-up
No change from baseline 1766 (71) 751 (64) 890 (63) 2130 (60)
First change in follow-up
Started HC – – – 1444 (40)
Switched HC type 421 (17) 267 (23) 236 (17) –
Stopped HC 312 (14) 162 (14) 284 (20) –
Values are n (%).
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Table III Incidence of human immunodeﬁciency virus (HIV) by HC (at enrolment).
DMPA (n 5 2499) Net-En (n5 1180) Oral contraception
(n 5 1410)
No hormonal
contraception (n5 3574)
Total
N5 8663
Overalla 146/2341 6.2 (5.3–7.3) 69/1102 6.3 (4.9–7.9) 50/1321 3.8 (2.9–5.0) 117/3358 3.5 (2.9–4.2) 382/8122 4.7 (4.3–5.2)
% person-years lost
Trial sites
Durban 62/920 6.7 (5.3–8.6) 29/279 10.4 (7.3–15.0) 9/186 4.8 (2.5–9.3) 33/821 4.0 (2.9–5.6) 133/2206 6.0 (5.1–7.1)
Johannesburg 27/389 7.0 (4.8–10.2) 32/683 4.7 (3.3–6.6) 9/300 3.0 (1.6–5.8) 40/819 4.9 (3.6–6.71) 108/2190 4.9 (4.1–6.0)
Africa Centre 22/329 6.7 (4.4–10.2) 6/76 7.9 (3.5–17.6) 6/63 9.5 (4.2–21.0) 10/481 2.1 (1.1–3.9) 44/950 4.6 (3.4–6.2)
Masaka 19/259 7.3 (4.7–11.5) 0 – 4/51 7.8 (2.9–20.1) 15/435 3.4 (2.1–5.7) 38/746 5.1 (3.7–7.0)
Mwanza 6/312 1.9 (0.9–4.3) 0 – 3/178 1.7 (0.5–5.2) 6/476 1.3 (0.6–2.8) 15/965 1.6 (0.9–2.6)
Mazabuka 10/133 7.5 (4.0–13.9) 2/64 3.1 (0.8–12.5) 19/543 3.5 (2.2–5.5) 13/324 4.0 (2.3–6.9) 44/1064 4.1 (3.1–5.6)
Age group
,25 years 84/939 8.9 (7.2–11.1) 47/668 7.0 (5.3–9.4) 25/490 5.1 (3.5–7.6) 59/889 6.6 (5.1–8.6) 215/2986 7.2 (6.3–8.2)
≥25 years 62/1401 4.4 (3.4–5.7) 22/434 5.1 (3.3–7.7) 25/831 3.0 (2.0–4.5) 58/2469 2.3 (1.8–3.0) 167/5136 3.3 (2.8–3.8)
HSV2 status at enrolment
Positive 107/1515 7.1 (5.8–8.5) 36/528 6.8 (4.9–6.0) 35/810 4.3 (3.1–6.0) 78/2327 3.4 (2.7–4.2) 256/5180 4.9 (4.4–5.6)
Negative/Equiv 39/826 4.7 (3.4–6.5) 33/574 5.8 (4.1–8.1) 15/510 2.9 (1.8–4.9) 39/1031 3.8 (2.7–5.2) 126/2942 4.3 (3.6–5.1)
Week 52 analysis. Values are # HIV infections/# person-years; HIV incidence per 100 person-years (95% conﬁdence interval (CI)).
aComparing rates across four HC groups: logrank P, 0.001.
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threat to the quality of data generated. In parallel to the planning of a ran-
domized trial, an individual patient data meta-analysis is underway, with
.1800 incident HIV infections in the combined 18 longitudinal datasets,
and this will determine the most precise estimates for DMPA and
Net-En so far.
WHO guidelines use the GRADE scheme to evaluate the evidence
taking account of study quality, the size of the effect and precision
around the estimate. A WHO Expert committee then reviews the
GRADEdevidence and considers the risk beneﬁt considerationsof chan-
ging current guidance on the use of DMPA in high HIV prevalence set-
tings, with particular attention being paid to any resulting rise in
unintended pregnancy and associated maternal mortality andmorbidity,
versus a reduction in HIVmorbidity andmortality (Butler et al., 2013). A
modest increase in risk for HIV acquisition does not justify withdrawal of
DMPA where this is the only available HC, and overall HIV incidence is
low. However this is not the case in South Africa, where HIV incidence
amongstwomen remains high, and alternativeHCmethods are available.
The current recommendation thatwomen at risk ofHIV use condoms as
well asDMPA is of little use to a large proportion of women usingDMPA
as this study shows. The results of this study and other new data soon to
be published should be urgently reviewed by WHO to see if current
recommendations require modiﬁcation.
What is certain is that the majority of women who seek a long-acting
contraceptive method living in countries with a high prevalence of HIV
will continue to have little choice other than DMPA for the foreseeable
future. This is not an acceptable situation. A change in theWHOrecom-
mendations would undoubtedly accelerate the provision of alternative
long-acting contraceptives (such as intrauterine contraceptive devices
or hormonal implants) as well as the introduction of new methods.
However, the time has already come for greater investments by the
HIV and family planning ﬁelds to increase efforts towards this program-
matic goal.
Supplementary data
Supplementarydata areavailable athttp://humrep.oxfordjournals.org/.
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Table IV Estimated effect of HC on HIV acquisition.
(a) Univariable
model
Baseline
covariate
adjusted modela
Univariable
model
Baseline
covariate
adjusted modela
Time-updated
covariate adjusted
modela
Contraception Baseline Baseline Current Current Current
DMPA 1.79 (1.41–2.28) 1.38 (1.07–1.78) 1.86 (1.43–2.41) 1.33 (1.01–1.75) 1.45 (1.09–1.93)
Net-En 1.80 (1.34–2.43) 1.18 (0.86–1.62) 1.81 (1.32–2.47) 1.07 (0.77–1.50) 1.20 (0.84–1.69)
OC 1.09 (0.78–1.52) 0.97 (0.68–1.38) 1.06 (0.77–1.47) 0.84 (0.60–1.18) 0.90 (0.63–1.26)
No HC 1 1 1 1 1
LRT
P-valuec
,0.001 0.062 ,0.001 0.020 0.008
(b) Univariable
model
Baseline covariate
adjusted modela
Inverse probability
weighted modelb
Contraception Baseline Baseline
DMPA 2.29 (1.68–3.11) 1.46 (1.05–2.04) 1.49 (1.06–2.08)
Net-En 2.43 (1.69–3.48) 1.33 (0.89–1.99) 1.31 (0.86–1.99)
OC 0.99 (0.87–1.97) 1.00 (0.64–1.58) 1.00 (0.62–1.61)
No HC 1 1 1
LRT
P-valuec
,0.001 0.085 0.067
Values are estimated hazard ratios (95% CI) (a) Week 52 analysis (based on 382 HIV infections); (b) Week 52 analysis, censored for changing HC and pregnancy (based on 282 HIV
infections).
aModels adjusted for age, centre, HSV-2 result, chlamydia result, bacterial vaginosis, vaginal discharge, frequency of sex and condom use, pregnancy (time-updated model only) and
randomization.
bWeights for inverse probability weighted (IPW) model computed from separate, within centre, multinomial logistic regression models for use of HC and censoring in follow-up and
pregnancy, including the variables listed above (except pregnancy) and education, employment status, genital ulcers, genital itching, ectopy and other sexually transmitted infection results.
Weights, mean (range): 1.00 (0.14–4.09).
cLikelihood ratio test P-values comparing the effects of the contraceptive methods.
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